

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
09 March 2023 (09.03.2023)



(10) International Publication Number
WO 2023/034817 A4

(51) International Patent Classification:

A61K 47/64 (2017.01) C12N 15/113 (2010.01)
C07K 7/64 (2006.01)

(21) International Application Number:

PCT/US2022/075691

(22) International Filing Date:

30 August 2022 (30.08.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/239,645	01 September 2021 (01.09.2021)	US
63/239,671	01 September 2021 (01.09.2021)	US
63/290,960	17 December 2021 (17.12.2021)	US
63/292,685	22 December 2021 (22.12.2021)	US
63/298,565	11 January 2022 (11.01.2022)	US
63/268,577	25 February 2022 (25.02.2022)	US
63/268,580	25 February 2022 (25.02.2022)	US
63/362,294	31 March 2022 (31.03.2022)	US
63/362,423	04 April 2022 (04.04.2022)	US
63/337,560	02 May 2022 (02.05.2022)	US
63/354,456	22 June 2022 (22.06.2022)	US

(71) Applicant: **ENTRADA THERAPEUTICS, INC.**
[US/US]; 6 Tide Street, Boston, Massachusetts 02210 (US).

(72) Inventors: **LI, Xiang**; 6 Tide Street, Boston, Massachusetts 02210 (US). **QIAN, Ziqing**; 6 Tide Street, Boston, Massachusetts 02210 (US). **KHEIRABADI, Mahboubeh**; 6 Tide Street, Boston, Massachusetts 02210 (US). **WYSK, Mark**; 6 Tide Street, Boston, Massachusetts 02210 (US). **SETHU-RAMAN, Natarajan**; 6 Tide Street, Boston, Massachusetts 02210 (US). **LIAN, Wenlong**; 6 Tide Street, Boston, Massachusetts 02210 (US). **GIRGENRATH, Mahsweta**; 6 Tide Street, Boston, Massachusetts 02210 (US). **ESTRELLA, Nelsa**; 6 Tide Street, Boston, Massachusetts 02210 (US).

(74) Agent: **PERDOK, Monique M.** et al.; P.O. Box 2938, Minneapolis, Minnesota 55402 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with amended claims (Art. 19(1))

Date of publication of the amended claims:

13 April 2023 (13.04.2023)

(54) Title: COMPOUNDS AND METHODS FOR SKIPPING EXON 44 IN DUCHENNE MUSCULAR DYSTROPHY

(57) Abstract: Described herein in various embodiments are compositions comprising (a) a cyclic peptide; and (b) an antisense compound, wherein the antisense compound targets exon 44 of the DMD gene in a pre-mRNA sequence.

WO 2023/034817 A4